PLAT and Stroke: Considering that tPA is the first and only choice therapeutic for stroke patients [3–5], and all newly developed neuroprotectants would eventually be used as a combination therapy (unless there are adverse interactions), the recommendation for extensive in vitro combination testing should be made and adhered to.